axovant
announces
positive
data
second
cohort
phase
trial
gene
therapy
serious
adverse
events
months
mean
improvement
updrs
part
iii
score
improvement
baseline
exceeding
criteria
success
greater
improvement
baseline
diary
good
time
diary
time
assessments
randomized
study
expected
begin
dosing
new
york
globe
newswire
axovant
gene
therapies
nasdaq
axgt
gene
therapy
company
developing
innovative
gene
therapies
neurodegenerative
diseases
today
reported
data
second
cohort
patients
receiving
total
dose
x
tu
gene
therapy
phase
trial
treatment
parkinson
disease
data
showing
points
improvement
updrs
part
iii
motor
function
score
well
meaningful
improvements
quality
life
measures
underscores
potentially
profile
gene
therapy
parkinson
disease
totality
data
seen
thus
far
reinforces
belief
potential
transform
treatment
patients
parkinson
disease
administration
gene
therapy
building
encouraging
results
expect
begin
dosing
randomized
study
additionally
evaluate
safety
tolerability
higher
volumes
infusion
look
forward
sharing
additional
data
program
updates
upcoming
parkinson
disease
r
day
october
said
gavin
corcoran
chief
r
officer
axovant
key
study
results
months
observed
generally
patients
receiving
gene
therapy
serious
adverse
events
attributable
vector
six
months
single
administration
subjects
average
age
years
average
duration
parkinson
disease
years
two
evaluable
patients
cohort
demonstrated
mean
improvement
updrs
part
iii
score
assesses
motor
function
representing
improvement
baseline
average
score
patients
improvement
updrs
part
iii
score
cohort
exhibited
evidence
dose
response
compared
cohort
low
medium
high
dose
cohorts
prosavin
previously
evaluated
separate
phase
study
improvement
updrs
part
iii
score
cohort
exhibited
evidence
dose
response
compared
cohort
low
medium
high
dose
cohorts
prosavin
previously
evaluated
separate
phase
study
patient
refusal
patients
cohort
clinical
trial
sites
unable
participate
updrs
assessments
mandatory
washout
background
levodopa
therapy
time
point
however
subjects
able
complete
efficacy
assessments
months
including
hauser
diaries
company
working
sites
investigators
ensure
safe
ethical
data
collection
future
time
points
pandemic
accordance
regulatory
guidance
diary
good
time
defined
sum
time
without
dyskinesias
time
dyskinesias
improved
average
hours
baseline
good
time
hours
across
four
patients
patients
demonstrated
improvement
baseline
diary
good
time
patients
demonstrated
improvement
baseline
diary
good
time
diary
time
defined
time
medication
worn
longer
providing
benefit
regards
mobility
improved
average
hours
baseline
time
hours
across
four
patients
patients
demonstrated
improvement
baseline
diary
time
patients
demonstrated
improvement
baseline
diary
time
two
evaluable
patients
cohort
demonstrated
mean
improvement
updrs
part
ii
score
assesses
activities
daily
living
representing
improvement
baseline
completion
cohort
company
expects
investigate
safety
tolerability
higher
volume
flow
rate
increase
putaminal
coverage
decrease
operating
room
time
cohort
successful
development
manufacturing
process
axovant
expects
dose
first
patient
additional
program
updates
provided
axovant
parkinson
disease
r
day
october
pavan
cheruvu
md
chief
executive
officer
axovant
added
highly
encouraged
growing
evidence
dose
response
apparent
clinical
improvement
observed
study
combined
favorable
safety
profile
results
exceed
base
case
criteria
points
improvement
baseline
updrs
part
iii
score
threshold
considered
clinically
meaningful
medical
literature
compared
standard
care
although
pandemic
impacted
ability
collect
full
updrs
data
cohort
safety
patients
staff
first
priority
begun
work
validating
new
technologies
may
enable
clinical
assessments
future
time
points
order
obtain
complete
data
sets
based
data
seen
thus
far
excited
advance
clinical
development
program
first
randomized
controlled
study
evaluate
continuous
dopamine
replacement
strategy
gene
therapy
parkinson
disease
investigational
gene
therapy
treatment
parkinson
disease
designed
deliver
three
genes
tyrosine
hydroxylase
cyclohydrolase
aromatic
acid
decarboxylase
via
single
lentiviral
vector
encode
set
critical
enzymes
required
dopamine
synthesis
goal
reducing
variability
restoring
steady
levels
dopamine
brain
investigational
gene
therapy
aims
provide
patient
benefit
years
following
single
administration
axovant
expects
dose
first
patient
randomized
sham
controlled
study
axovant
axovant
gene
therapies
gene
therapy
company
focused
developing
pipeline
innovative
product
candidates
debilitating
neurodegenerative
diseases
current
pipeline
gene
therapy
candidates
targets
gangliosidosis
gangliosidosis
also
known
disease
sandhoff
disease
parkinson
disease
axovant
focused
accelerating
product
candidates
clinical
trials
team
experts
gene
therapy
development
external
partnerships
leading
gene
therapy
organizations
information
visit
statements
press
release
contains
statements
purposes
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
use
words
may
might
would
expect
believe
estimate
similar
expressions
intended
identify
statements
example
statements
axovant
makes
regarding
costs
associated
operating
activities
statements
based
estimates
assumptions
axovant
management
although
axovant
believes
reasonable
inherently
uncertain
statements
subject
risks
uncertainties
may
cause
actual
results
differ
materially
axovant
expected
risks
uncertainties
include
among
others
impact
pandemic
operations
initiation
conduct
preclinical
studies
clinical
trials
availability
data
clinical
trials
scaling
manufacturing
expectations
regulatory
submissions
approvals
continued
development
gene
therapy
product
candidates
platforms
axovant
scientific
approach
general
development
progress
availability
commercial
potential
axovant
product
candidates
statements
also
subject
number
material
risks
uncertainties
described
axovant
recent
quarterly
report
form
filed
securities
exchange
commission
august
updated
subsequent
filings
securities
exchange
commission
statement
speaks
date
made
axovant
undertakes
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
contacts
media
contact
josephine
belluardo
lifesci
communications
jo
media
investors
analysts
david
nassif
axovant
gene
therapies
chief
financial
officer
general
counsel
investors
